


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院

nzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

VOLUNTARY ANNOUNCEMENT PRINCIPAL OPERATING DATA AND INDICATORS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 AND THE THIRD QUARTER 2022

This is a voluntary announcement made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The table below sets forth the relevant operating data and indicators of the Group’s owned hospitals by inpatients and outpatients for the nine months ended September 30, 2022 with comparative figures for the nine months ended September 30, 2021:

	For the nine months ended September 30,		Year- on-year changes
	2022	2021	
Inpatients			
Number of inpatient bed-days	2,324,635	2,032,082	14.4%
Average inpatient spending per bed-day on treatment and general healthcare services (RMB)	340	327	4.0%
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	50	54	-7.4%
Total average inpatient spending per bed-day (RMB)⁽¹⁾	390	380	2.6%
Outpatients			
Number of outpatient visits ⁽²⁾	342,293	264,347	29.5%
Average outpatient spending per visit on treatment and general healthcare services (RMB) ⁽²⁾	123	130	-5.4%
Average outpatient spending per visit on pharmaceutical sales (RMB)	322	327	-1.5%
Total average outpatient spending per visit (RMB)	445	458	-2.8%

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the three months (the third quarter) from July 1, 2022 to September 30, 2022 with comparative figures of the same period in 2021:

	Three months from July 1 to September 30,		Year- on-year changes
	2022	2021	
Inpatients			
Number of inpatient bed-days	819,136	716,589	14.3%
Average inpatient spending per bed-day on treatment and general healthcare services (<i>RMB</i>)	345	331	4.2%
Average inpatient spending per bed-day on pharmaceutical sales (<i>RMB</i>)	50	52	-3.8%
Total average inpatient spending per bed-day (<i>RMB</i>)⁽¹⁾	<u>395</u>	<u>383</u>	<u>3.1%</u>
Outpatients			
Number of outpatient visits ⁽²⁾	117,261	96,771	21.2%
Average outpatient spending per visit on treatment and general healthcare services (<i>RMB</i>) ⁽²⁾	132	137	-3.6%
Average outpatient spending per visit on pharmaceutical sales (<i>RMB</i>)	321	314	2.2%
Total average outpatient spending per visit (<i>RMB</i>)	<u>453</u>	<u>451</u>	<u>0.4%</u>

Notes:

1. The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.
2. The above data of number of outpatient visits and average outpatient spending per visit on treatment and general healthcare services are excluding the business of the COVID-19 nucleic acid test.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data may be different from those disclosed in periodical reports. The operating data disclosed in periodical reports shall prevail if there is any discrepancy. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

CONTINUED TRADING SUSPENSION

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on April 1, 2022. Trading in the shares of the Company will remain suspended until further notice.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
October 3, 2022

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili and Ms. WANG Lianyue; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Mr. ZHAO Xudong, Ms. ZHONG Wentang and Mr. LIU Ning.